heart-beat
92
M

patients have cardiovascular disease in the US1

head-breath
60
%

also suffer from sleep apnea2

statoscope
85
%

remain undiagnosed3

heart_animation

% RISK

Undiagnosed sleep apnea is a major comorbidity of CVD and a significant risk factor for stroke, CAD, CHF and AFib4. Sleep apnea puts an enormous strain on the heart and remodels the cardiac substrate through stretching, oxidative stress and frequent sympathetic surges5. Diagnosing sleep apnea at home with the WatchPAT®️ home sleep apnea diagnosis device improves compliance leading to better patient outcomes.

Drug Resistant Hypertension
83
%
Congestive Heart Failure
76
%
Stroke
72
%
Arrythmias
58
%
Atrial Fibrillation
49
%
Ischemic Heart Disease
38
%

AHA recommends that screening for sleep apnea risk should be integrated into routine clinical care6.

The use of CPAP is associated with a 42% relative risk reduction in AFib recurrence in patients with OSA. This reduction of AFib recurrence appears to be independent of medical or catheter ablation therapy. These results advocate for active screening for undiagnosed OSA in patients with AFib when OSA is clinically suspected7. A simple yes/no questionnaire called STOP-BANG takes just a few minutes to identify those patients with a high probability of obstructive sleep apnea.

TOTAL SLEEP SOLUTIONS

Screening-icon
Screening
Screening
More than 80% of cardiovascular patients remain undiagnosed or untreated for sleep apnea. A simple questionnaire can help you identify patients who may be at risk for sleep apnea, making them eligible for a diagnostic sleep test.
Diagnosis-icon
Diagnosis
Diagnosis
To be eligible for insurance coverage for sleep apnea therapy, your patients need a validated diagnosis.
Diagnosis is obtained with an
easy to use sleep study, performed at the patient’s home.
Treatment-icon
Treatment
Treatment
Adequately treated sleep apnea has been associated with improved cardiovascular outcomes and lower rates of hospital readmission.
Reporting-icon
Reporting
Reporting
The success of sleep apnea therapy depends on patients’ compliance. Compliance to therapy should be optimized to improve cardiovascular outcomes. Your patients will benefit from your staying informed and updated on their progress.

Total Sleep Solutions is a novel cross-disciplinary model of care developed in collaboration with cardiologists, sleep physicians and industry partners for the management of cardiac patients.
It expands the reach of sleep services by enabling point of care variability, providing a scalable model for management of a massive volume of patients’ while reducing wait times and overall cost, and offering optimized IT systems and human field resources to support the vast underdiagnosed pool of cardiac patients suffering from the co-morbidity of Sleep Apnea.

We will work with you to set up a complete patient care pathway from diagnosis through to therapy with the WatchPAT Home Sleep Apnea Test.

Testimonials and More

Dr. David Vorchheimer - Sleep Apnea Managment in Cardiology Practice
Dr. Randy Lieberman - The impacts of Obstructive Sleep Apnea on the overall cardiovascular system
Itamar Medical - World's leading Sleep Apnea Solutions to the Cardiology Market
Total Sleep Solutions

References on this page:

  1. Heart Disease and Stroke Statistics 2017 At-a-Glance.
  2. Obstructive Sleep Apnea in Cardiovascular Disease Tietjens et al, Journal of the American Heart Association, 2018
  3. Sleep Apnea and Cardiovascular Disease, JACC Vol. 52, No. 8, 2008, August 19, 2008:686–717
  4. Obstructive Sleep Apnea: Preoperative Assessment, Seet & Chung, Anesthesiology Clin 28 (2010) 199–215.
  5. Anter E. Circulation: Arrhythmia and Electrophysiology. 2017, Atrial Substrate and Triggers of Paroxysmal Atrial Fibrillation in Patients with Obstructive Sleep Apnea.
  6. Circulation. November 2016, Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health.
  7. Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence Shukla, Chinitz JACC Clinical Electrophysiology Vol 1 ,No 1-2 , 2015
Site by Imaginet
Site by Imaginet

Accessibility Toolbar